Safety and Efficacy Registry of Yinyi? stent (SERY)


Type: Prospective, Clinical Registry
Principal Investigator:
Weifeng Shen, MD, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Guoying Zhu, MD, Wuhan Asia Heart Hospital
CRO: Beijing Meihua Medical Information Company
Core Lab: Shanghai Jiaotong University, Cardiovascular Institute
Sponsor: Liaoning Biomedical Materials R&D Center Co., Ltd.


Yinyi? Polymer-free Paclitaxel-Eluting Coronary Stent


1045 patients

Primary Endpoint

MACE at 12, 24, 36 months
MACE = Death, MI, TLR

Secondary Endpoints

1.Stent thrombosis at 36 months (ARC Definition)
2.Restenosis & Late lumen loss at 9-12 months

Clinical Results

SERY was the first large-scale clinical trial of YINYI polymer-free paclitaxel-eluting coronary stent after it was launched in 2008. As a study focused on polymer-free DES, SERY had a largest enrolled number in the world range at that time. There were 27 sites enrolled 1045 patients, and 1713 YINYI were implanted. The primary and secondary endpoints had been reported successively in GW-ICC during 2010-2012, and the results were exciting.

Polymer-free DES accelerates the endothelialization on the basis of lower restenosis. There is no late catch-up or late stent thrombosis while durable polymer DES has. SERY trial demonstrated YINYI polymer-free PES has DES's efficacy and BMS's safety.

上海十一选五最新开奖结果 怎样分析股票涨跌 000636股票行情 河南快三基本走势图一定牛 群英会任二追号 时时彩网站注册官网 河南十一选五走势图 有没有江西快3网址 腾讯分分彩真假改单 中国福利彩票快乐十分 内蒙11选5走势图真准 河北快3开奖结果走试图 梦之城之娱乐 3d试机号公式 股票分析软件排名 江西快三彩票app 北京快乐8在哪可买